TLDR
- Eli Lilly has filed six lawsuits against U.S. companies selling black-market versions of its experimental obesity drug, retatrutide
- Retatrutide is still in Phase 3 clinical trials and has not been approved by the FDA for human use
- The defendants include compounding pharmacies, medical spas, and online sellers
- U.S. Customs and Border Protection intercepted over 1,400 shipments of illicit GLP-1 drugs in July alone, nearly 90,000 vials
- Lilly has referred more than 200 individuals and entities to federal and state law enforcement agencies
Eli Lilly (LLY) is taking legal action against six U.S. companies it says are illegally selling black-market versions of its experimental weight-loss drug retatrutide. LLY stock was trading down 0.68% on Wednesday.
The lawsuits target Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide. The defendants span a range of business types, including compounding pharmacies, medical spas, and online resellers.
Retatrutide is currently in Phase 3 clinical trials for obesity, type 2 diabetes, and related conditions. No regulator has approved the drug for human use.
The FDA made its position clear in June, stating that sales of retatrutide and other unapproved GLP-1 products are illegal and cannot lawfully be compounded.
“What is being sold on the black market is not a medicine. It is entirely unverified, unapproved and not worth the risk,” said Lilly Chief Medical Officer Dr. David Hyman.
Despite that, demand for obesity treatments has created a thriving online market. Some sellers have marketed retatrutide through websites, social media, and businesses presenting themselves as legitimate medical providers.
Lilly says these sellers are sourcing products from unregulated manufacturers, raising serious patient safety concerns.
Lilly Escalates Enforcement Push
Beyond the six lawsuits, Lilly has referred more than 200 individuals and entities to the FDA, the U.S. Justice Department, state attorneys general, and law enforcement agencies.
The company is also calling on social media platforms, e-commerce sites, payment processors, credit card companies, and shipping firms to take stronger action against sellers of unapproved retatrutide products.
“Every single time that someone takes one of these, they’re exposing themselves to a huge amount of risk,” said Dr. Max Denning, Lilly’s Associate Vice President and Therapeutic Area Lead for Global Patient Safety, Cardiometabolic Health.
Seizures Surging at the Border
The scale of the problem is growing fast. U.S. Customs and Border Protection intercepted over 690 shipments, totaling more than 31,000 units, of illicit GLP-1 drugs during fiscal year 2025.
In July alone, those numbers more than doubled. Customs agents recorded over 1,400 seizures and intercepted nearly 90,000 vials in a single month.
The surge in seizures points to how quickly the black market for unapproved GLP-1 drugs has grown, driven by consumer demand for weight-loss treatments.
Lilly’s campaign against unauthorized retatrutide sellers began before the current round of lawsuits. Wednesday’s filings represent its most direct legal action yet against named defendants.
The six companies named in the lawsuits are Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
